SV

Street Verdict

Analyst Scorecard

A record of what Riyank Arora said publicly, with the source. Not advice.

“Bullish on Glenmark Pharmaceuticals for the short term, recommending a buy with a target of ₹1,830 and a stop-loss at ₹1,400. The stock has decisively broken above its trendline resistance at ₹1,518 and is trading above key moving averages, signaling a strong bullish trend. The pharmaceutical sector is at crucial support, positioning Glenmark for further upside, with RSI (14) around 65 indicating strong momentum.”

Riyank Arora’s track record (trackable calls only): 124 graded calls · 95% CI 23–39%

Glenmark PharmaceuticalsBullishCalled 01 Apr 2025Graded 09 Apr 2025
Verdict:MISS

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,830, stop ₹1,400, as stated.

Window: 30 days, from the call's own horizon word ("for the short term").

The stop ₹1,400 was reached on a close before the target ₹1,830. Miss.

The grader’s working: R4 TARGET_CALL: entered ₹1515.45 on 2025-04-02 (next trading session's close); stop ₹1400 breached at close ₹1376.3 on 2025-04-09. Window 30 days — rule H4: the quote says "for the short term" (short-term 30 days, medium-term 90, long-term 12 months).

Tracking Glenmark Pharmaceuticals since this call

1-year tracking window
Read the original articleSee Riyank Arora’s full track record